Patients with the rare DNASE1L3 biallelic null mutation present with childhood-onset disease that resembles lupus. This observation prompted research into how abnormalities in the enzyme DNASE1L3 are associated with lupus, with researchers finding autoantibody-mediated impairment of DNASE1L3 activity may be a common non-genetic mechanism leads to anti-dsDNA autoreactivity in SLE.
ATLANTA—The American College of Rheumatology (ACR), in partnership with the Vasculitis Foundation (VF), released three new guidelines for the treatment and management of systemic vasculitis. Vasculitis is a group of about 20 rare diseases that have inflammation of blood vessels in common, which can restrict blood flow and damage vital organs. The three guidelines cover…
This year’s global event offers an interactive, educational and exciting conference, with networking opportunities, insights into clinical and basic research and more.
A delayed second dose of an mRNA vaccine may provide better protection against COVID-19 in elderly patients.
Hesitancy about COVID-19 vaccination persists nationwide, although it varies among regions and sociodemographic groups.
Amid rising drug costs and the growing influence of pharmacy benefit managers on patient care decisions, physicians are increasingly called upon to advocate for affordable, evidence-based treatments for their patients.
Based on data from two phase 3 clinical trials, Health Canada has approved the use of upadacitinib to treat adults with active psoriatic arthritis.
A recent study demonstrated that exposure to type I interferon contributes to the pathogenesis of SLE via the metabolic rewiring of CD8+ T cells, which promotes cell death.
The ACR is accepting applications for this year’s Advocates for Arthritis event, which will be held virtually on Sept. 27–28. This annual event brings together patients and rheumatology professionals to advocate for our subspecialty on Capitol Hill. Applications are also open for the Advocacy 101 program, which provides advocacy training for ACR/ARP members. Apply today…
In an efficacy and safety study of guselkumab, patients with active psoriatic arthritis taking guselkumab showed continued skin clearance and joint symptom relief, as well as statistically significant inhibition of joint damage, after two years.